Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market Forecast 2026: Market Size, Competitive Landscape And Growth Drivers
Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market Revenue Growth On Track For A 8.6% CAGR Through 2030
The market size for antineutrophil cytoplasmic antibody (anca) associated vasculitis has demonstrated robust expansion in recent years. Forecasts indicate it will increase from $0.63 billion in 2025 to $0.68 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.7%. This historical growth can be linked to several factors, including improvements in autoimmune disease diagnostics, increased use of corticosteroids and immunosuppressants, the expansion of nephrology and rheumatology care services, growing clinical awareness of rare vasculitis disorders, and the availability of standardized treatment protocols.
The antineutrophil cytoplasmic antibody (anca) associated vasculitis market size is anticipated to demonstrate significant expansion in the upcoming years. It is projected to reach $0.95 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.6%. This growth over the forecast period is fueled by factors such as the increasing development of targeted biologics, rising investments in rare disease research, the expansion of personalized treatment approaches, a growing focus on strategies for relapse prevention, and enhanced patient access to specialized care centers. Significant trends expected during this timeframe include a greater adoption of biologic therapies, an elevated focus on early and accurate diagnosis, the increasing use of targeted immunosuppressive treatments, the broadening of multidisciplinary disease management approaches, and a stronger emphasis on long-term disease monitoring.
Get A Free Sample Report With In-Depth Market Insights:
Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market Industry Drivers: What’s Behind The Revenue Growth?
The expanding occurrence of autoimmune diseases is projected to drive the growth of the ANCA-associated vasculitis market moving forward. Autoimmune diseases are conditions where the immune system incorrectly targets the body’s own healthy cells and tissues, mistaking them for external threats like bacteria or viruses. The escalating incidence of autoimmune diseases is attributable to environmental triggers and lifestyle factors, with increased exposure to infections and pollutants playing a significant role by disrupting immune tolerance and initiating abnormal immune responses. Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis contributes positively to advancing autoimmune disease research and treatment by stimulating the development of targeted immunosuppressive therapies, improving early diagnostic capabilities, and enhancing overall disease management strategies, ultimately leading to better patient outcomes and a deeper understanding of immune system regulation. For instance, in September 2023, according to the Impact of IBD Report 2023 published by the Inflammatory Bowel Disease (IBD) Clinical and Research Centre, a Canada-based organization that aims to improve the lives of patients with Crohn’s disease and ulcerative colitis, in 2023, the prevalence of inflammatory bowel disease (IBD) (an autoimmune disease) in Canada was 825 per 100,000 people, affecting over 320,000 individuals. With an expected annual increase of 2.44% in prevalence, it is projected that by 2035, approximately 470,000 Canadians, representing 1.1% of the population, will be living with IBD. Therefore, the rising incidence of autoimmune diseases will propel the ANCA-associated vasculitis market.
Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market Breakdown By Product Type And Application
The antineutrophil cytoplasmic antibody (anca) associated vasculitis market covered in this report is segmented –
1) By Type: Granulomatosis With Polyangiitis (GPA Or Wegener’s), Microscopic Polyangiitis (MPA), Eosinophilic Granulomatosis With Polyangiitis (EGPA Or Churg-Strauss), Other Types
2) By Treatment: Immunosuppressants, Corticosteroids, Biologics, Other Treatments
3) By Diagnosis: Blood Tests, Biopsy, Imaging, Other Diagnosis
Subsegments:
1) By Granulomatosis With Polyangiitis (GPA or Wegener’s): Limited Granulomatosis With Polyangiitis, Severe Granulomatosis With Polyangiitis, Refractory Granulomatosis With Polyangiitis
2) By Microscopic Polyangiitis (MPA): Renal Microscopic Polyangiitis, Pulmonary Microscopic Polyangiitis, Neurological Microscopic Polyangiitis
3) By Eosinophilic Granulomatosis With Polyangiitis (EGPA or Churg-Strauss): Cardiac Eosinophilic Granulomatosis With Polyangiitis, Pulmonary Eosinophilic Granulomatosis With Polyangiitis, Neurological Eosinophilic Granulomatosis With Polyangiitis
4) By Other Types: Drug-Induced ANCA-Associated Vasculitis, Infection-Related ANCA-Associated Vasculitis, Overlap Syndrome ANCA-Associated Vasculitis
#Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market Growth Trends: What’s Shaping The Future Outlook?
Major companies in the ANCA-associated vasculitis market are concentrating on developing innovative solutions, such as targeted therapies, to provide new treatment options for patients suffering from this rare and serious disease. Targeted therapy for ANCA-associated vasculitis involves utilizing specialized biologic agents to selectively inhibit immune system components responsible for inflammation and vascular damage, thereby reducing disease progression and minimizing treatment-related toxicity. For instance, in February 2023, Vifor Fresenius Medical Care Renal Pharma (VFMCRP), a Switzerland-based pharmaceutical company, announced the approval of Tavneos (avacopan) by the Therapeutic Goods Administration (TGA), an Australia-based government regulatory agency, for treating anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV) when used in combination with a rituximab or cyclophosphamide-based regimen. This approval signifies a substantial advancement as Tavneos is the first targeted therapy designed specifically for granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), which are the two primary forms of ANCA-associated vasculitis. By selectively inhibiting the complement C5a receptor (C5aR1), the therapy assists in controlling inflammation and disease progression while also reducing the dependence on high-dose glucocorticoids (steroids), known for their severe long-term side effects.
Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market Company Landscape And Competitive Strategy
Major companies operating in the antineutrophil cytoplasmic antibody (anca) associated vasculitis market are ChemoCentryx Inc, Amgen Inc, AstraZeneca Plc, GlaxoSmithKline plc, Novartis AG, Bristol-Myers Squibb Company, Travere Therapeutics Inc, F. Hoffmann-La Roche AG, Pfizer Inc, Sanofi SA, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, AbbVie Inc, UCB S.A., Bayer AG, Janssen Pharmaceuticals NV, Sobi AB, Alentis Therapeutics AG, InflaRx NV, NS Pharma Inc, Staidson Biopharmaceuticals Co Ltd, Genentech Inc, Regeneron Pharmaceuticals Inc, Mylan NV, Teva Pharmaceutical Industries Ltd, Biogen Inc, CSL Limited, Moderna Inc, Vertex Pharmaceuticals Inc.
View The Full Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market Report:
Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market Geographic Spread And Regional Opportunities
North America was the largest region in the antineutrophil cytoplasmic antibody (ANCA) associated vasculitis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the antineutrophil cytoplasmic antibody (anca) associated vasculitis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
